TL6: Recent Advances in Turning Adaptive Designs Theory for Phase I Oncology Trials into Practice
*Inna Perevozskaya, Pfizer Keywords: phase 1 oncology. maximum tolerated dose, adaptive design Phase 1 oncology drug development recently has experienced a surge in usage of adaptive trial designs. When carefully designed and executed, such trials can offer significant advantage over 3+3 design in precision of Maximum Tolerated Dose estimation. There are quite a few adaptive options available for phase 1 oncology trials today; the level of their utilization varies greatly within pharmaceutical industry and academia alike. In this roundtable discussion, we will focus on case studies and actual experiences of planning and running these trials, including what it takes to make these methods broadly acceptable and what challenges are faced along the way.
|
Key Dates
-
November 1 - December 17, 2013
Online proposal submission for a session, short course and Town Hall Open -
January 6 - March 11, 2014
Online proposal submission for Roundtables Open -
April 30 - May 28, 2014
Abstract Submission Open -
June 4, 2014
Online Registration Opens -
August 8 - August 22, 2014
Invited Abstract Editing -
August 11, 2014
Short Course materials due from Instructors -
September 1, 2014
Housing Deadline -
September 15, 2014
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 22 - September 24, 2014
Marriott Wardman Park, Washington, DC